STOCK TITAN

[6-K] Evotec SE American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreiben Sie den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreiben Sie den folgenden Text um:

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July, 2025

 

 

COMMISSION FILE NUMBER 001-34041

 

Evotec SE
(Translation of registrant’s name into English)

 

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 

 

On July 21, 2025, Evotec SE (the “Company”) issued an Ad hoc announcement. A copy of the Ad hoc announcement is attached as Exhibit 99.1 hereto and Corporate News attached as Exhibit 99.2.

 

EXHIBIT INDEX

 

 

Exhibit Description of Exhibit
99.1Evotec SE adjusts revenue guidance while confirming profit guidance
99.2.Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix

 

 

 

 

SIGNATURE

 

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

     
  Evotec SE
     
     
  By: /s/ Paul Hitchin
    Name: Paul Hitchin
    Title: Chief Financial Officer

Date: July 21, 2025

 

 

 

FAQ

What information is available?

This document appears to contain limited substantive content.
Evotec Ag

NASDAQ:EVO

EVO Rankings

EVO Latest News

EVO Stock Data

1.46B
355.26M
2.52%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg